13G Filing: Point72 Asset Management and Global Blood Therapeutics Inc. (GBT)

Published on October 4, 2017 at 11:23 am by Insider Monkey Staff in Hedge Funds

Page 1 of 11

Global Blood Therapeutics Inc (NASDAQ:GBT): Steve Cohen’s Point72 Asset Management filed an amended 13D.

You can check out Point72 Asset Management’s latest holdings and filings here.

Please follow Point72 Asset Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Point72 Asset Management or update its stock holdings.

Steve Cohen

Point72 Asset Management

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name	Shared Voting Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
Point7	2,268,800	2,268,800	2,268,800	5.2%
Point7	2,268,800	2,268,800	2,268,800	5.2%
Cubist Systematic Strategies	6,699	6,699	6,699	Less than 0.1%
Point7	828	828	828	Less than 0.1%
Steven A. Cohen	2,276,327	2,276,327	2,276,327	5.2%

Steve Cohen

Point72 Asset Management

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

Page 1 of 11 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. )*

GLOBAL BLOOD THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, Par Value $0.001 Per Share

(Title of Class of Securities)

37890U108

(CUSIP Number)

October 2, 2017

(Date of Event which Requires Filing

of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

	☐	Rule 13d-1(b)
	☒	Rule 13d-1(c)
	☐	Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Global Blood Therapeutics Inc. (NASDAQ:GBT)Follow Global Blood Therapeutics Inc. (NASDAQ:GBT)

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

Page 1 of 11

Next >>

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.

We may use your email to send marketing emails about our services. Click here to read our privacy policy.